Dividend Increase 005: Sanofi



Sanofi delivered 2015 business EPS up 8.5% on a reported basis and stable at constant exchange rates consistent with guidance

Executing on 2020 strategic roadmap

  • Key milestone in reshaping the portfolio with announcement of exclusive negotiations on business swap
  • Significant R&D alliances in oncology and diabetes
  • Praluent® launch progressing with significant U.S. market access for 2016
  • Toujeo®  available globally in over 20 countries, reaching sales of €98 million in Q4 2015

Recent achievements in advancing Sanofi’s R&D pipeline of innovative medicines

  • Dengvaxia®, the world’s first dengue vaccine, approved in Mexico, Brazil, El Salvador and the Philippines
  • Biologics License Application for sarilumab accepted for review by the FDA
  • FDA submission for priority review of once-daily combination of insulin glargine and lixisenatide

Sales growth in Pharmaceuticals, Vaccines and Animal Health in 2015

  • Aggregate Group sales(2) up 2.2%(3) (+9.7% at 2015 exchange rates) to €37,057 million
  • Genzyme continues to be a key driver with sales up 29.5% with strong momentum in multiple sclerosis
  • Vaccines sales were up 7.3% benefiting from double-digit growth in Emerging Markets(4)
  • Diabetes sales decreased 6.8% in line with October guidance, reflecting lower U.S. sales of Lantus®
  • Animal Health demonstrated strong performance with sales up 10.8% driven by NexGard®
  • Emerging Markets Aggregate sales increased 7.8%, driven by strong growth in China, up 19.5%

Solid financial results in 2015 while making significant investments in new product launches

  • Business EPS was €5.64, up 8.5% on a reported basis and stable at CER
  • Free Cash Flow up 12.2% to €8,132 million resulting in net debt of €7,254 million
  • Board proposes dividend of €2.93, the 22nd consecutive year of dividend growth



Azioni in portafoglio :4

Dividendi incassati :0

Nuovo dividendo annuo stimato :6.60

Yoc :2%

Payback :0%






Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google+ photo

Stai commentando usando il tuo account Google+. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )


Connessione a %s...